Written by Tofacitinib, marketed under the brand name Xeljanz, is a Janus kinase (JAK) inhibitor that is approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) for the treatment of several autoimmune and inflammatory diseases. The drug works by selectively inhibiting JAK enzymes, which play a crucial role in the signaling pathways that […]